Literature DB >> 8636395

Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone.

M Klin1, M Smogorzewski, Z Ni, G Zhang, S G Massry.   

Abstract

Post-heparin hepatic lipase activity is reduced in chronic renal failure (CRF). This could be due to reduced synthesis, decreased activity, and/or impaired secretion of the enzyme. Further, the factor(s) responsible for such derangements are not elucidated. We examined hepatic lipase metabolism in normal, 6-wk-old CRF rats, CRF-PTX (parathyroidectomized) rats, and CRF and normal rats treated with verapamil (CRF-V, normal-V) using liver homogenate, hepatic cell culture for 8 h, and in vitro liver perfusion. The Vmax of hepatic lipase in liver homogenate was significantly (P < 0.01) reduced and the Km was significantly (P < 0.01) increased in CRF rats, but the values were normal in CRF-PTX, CRF-V, and normal-V rats. Culture of hepatic cells for 8 h was associated with an increase in hepatic lipase activity but the increment in CRF rats was significantly (P < 0.01) lower than that of normal, CRF-PTX, CRF-V, and normal-V rats. Both parathyroid hormone (PTH)-(1-84) and 1-34 inhibited the production of hepatic lipase in cultured cells from normal, CRF-PTX, CRF-V, and normal-V rats. The expression of the mRNA of the hepatic lipase was significantly reduced in CRF animals with the ratio between it and that of house keeping gene G3DPH being 15 +/-3% compared to 40 +/- 1.3% in normal, 44+/-2.9% CRF-PTX, 44 +/- 5.4% in CRF-V, and 39 +/- 3.9% in normal-V rats. Infusion of heparin to the in vitro hepatic perfusion system increased the activity of hepatic lipase in the effluent in all groups of rat except in CRF animals. Infusion of PTH-(1-34) in dose of 10(-6) M into the liver perfusion system inhibited the increase in post-heparin hepatic lipase activity. The data show that in CRF (a) the mRNA of hepatic lipase is downregulated, and hepatic lipase production, activity and release are impaired, (b) that this is due to the state of secondary hyperparathyroidism of CRF since both acute and chronic excess of PTH were associated with these abnormalities, (c) and that prevention of excess PTH by PTX of CRF rats or blocking the effect of PTH by treatment with verapamil corrected the derangement in hepatic lipase metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636395      PMCID: PMC507295          DOI: 10.1172/JCI118657

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Selective deficiency of hepatic triglyceride lipase in uremic patients.

Authors:  R Mordasini; F Frey; W Flury; G Klose; H Greten
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

2.  Preparation, characterization, and measurement of hepatic lipase.

Authors:  C Ehnholm; T Kuusi
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Regulation of liver lipase. II. Involvement of the alpha 1-receptor.

Authors:  K Schoonderwoerd; W C Hülsmann; H Jansen
Journal:  Biochim Biophys Acta       Date:  1984-10-04

4.  Regulation of hepatic glycogenolysis by glucagon in male and female rats. Role of cAMP and Ca2+ and interactions between epinephrine and glucagon.

Authors:  R K Studer; K W Snowdowne; A B Borle
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

Review 5.  Lipolytic enzymes and plasma lipoprotein metabolism.

Authors:  P Nilsson-Ehle; A S Garfinkel; M C Schotz
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

6.  Secretion of triacylglycerol hydrolase activity by isolated parenchymal rat liver cells.

Authors:  H Jansen; C Kalkman; A J Zonneveld; W C Hülsmann
Journal:  FEBS Lett       Date:  1979-02-15       Impact factor: 4.124

7.  Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man.

Authors:  J Bagdade; A Casaretto; J Albers
Journal:  J Lab Clin Med       Date:  1976-01

8.  Receptor-operated calcium influx in rat hepatocytes. Identification and characterization using manganese.

Authors:  G E Kass; J Llopis; S C Chow; S K Duddy; S Orrenius
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

9.  Serum lipid and lipoprotein concentrations in chronic uremia.

Authors:  H E Norbeck; L Orö; L A Carlson
Journal:  Acta Med Scand       Date:  1976

10.  Synthesis and secretion of triacylglycerol lipase by cultured rat hepatocytes.

Authors:  E Leitersdorf; O Stein; Y Stein
Journal:  Biochim Biophys Acta       Date:  1984-07-06
View more
  24 in total

1.  Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.

Authors:  Nosratola D Vaziri; Jun Yuan; Zhenmin Ni; Susanne B Nicholas; Keith C Norris
Journal:  Clin Exp Nephrol       Date:  2011-10-19       Impact factor: 2.801

Review 2.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Clin Exp Nephrol       Date:  2013-08-24       Impact factor: 2.801

3.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

4.  Impaired postprandial lipemic response in chronic kidney disease.

Authors:  Jeffrey M Saland; Lisa M Satlin; Jeanna Zalsos-Johnson; Serge Cremers; Henry N Ginsberg
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

Review 5.  Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Authors:  Roberto Scarpioni; Marco Ricardi; Vittorio Albertazzi; Luigi Melfa
Journal:  World J Nephrol       Date:  2012-12-06

6.  Reduced hepatic synthesis of calcidiol in uremia.

Authors:  Josée Michaud; Judith Naud; Denis Ouimet; Christian Demers; Jean-Luc Petit; Francois A Leblond; Alain Bonnardeaux; Marielle Gascon-Barré; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

Review 7.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

Review 8.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 9.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

10.  Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.

Authors:  Kyubok Jin; Keith Norris; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.